CD8A and lung adenocarcinoma: Lung adenocarcinoma with TP53 mutation/STK11-EGFR wild-type was reported to have higher CD8+ T-cell density and PD-L1 expression than other tumor subtypes, and the group of patients had a prolonged progression-free survival from immunotherapy [37].